{
    "root": "175e1ffc-e390-41e1-a63a-42bc2e255071",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "POTELIGEO",
    "value": "20250313",
    "ingredients": [
        {
            "name": "mogamulizumab",
            "code": "YI437801BE",
            "drugbank_id": "https://go.drugbank.com/drugs/DB12498"
        },
        {
            "name": "citric acid monohydrate",
            "code": "2968PHW8QP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_31404"
        },
        {
            "name": "glycine",
            "code": "TE7660XO1C",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15428"
        },
        {
            "name": "polysorbate 80",
            "code": "6OZP39ZG8H",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_53426"
        },
        {
            "name": "sodium hydroxide",
            "code": "55X04QC32I",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32145"
        },
        {
            "name": "hydrochloric acid",
            "code": "QTT17582CB",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_37527"
        },
        {
            "name": "water",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        }
    ],
    "indications": {
        "text": "poteligeo indicated treatment adult patients relapsed refractory mycosis fungoides ( mf ) s\u00e9zary syndrome ( ss ) least one prior systemic therapy .",
        "doid_entities": [
            {
                "text": "mycosis (DOID:1564)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1564"
            },
            {
                "text": "mycosis fungoides (DOID:8691)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8691"
            },
            {
                "text": "syndrome (DOID:225)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_225"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "1 mg/kg intravenous infusion least 60 minutes days 1 , 8 , 15 , 22 first 28-day cycle days 1 15 subsequent cycle ( 2 ) .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "poteligeo ( mogamulizumab-kpkc ) injection sterile , preservative-free , clear slightly opalescent colorless solution supplied carton containing one 20 mg/5 ml ( 4 mg/ml ) , single-dose glass vial ( ndc 42747-761-01 ) .",
    "adverseReactions": "none .",
    "indications_original": "POTELIGEO is indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or S\u00e9zary syndrome (SS) after at least one prior systemic therapy.",
    "contraindications_original": "1 mg/kg as an intravenous infusion over at least 60 minutes on days 1, 8, 15, and 22 of the first 28-day cycle and on days 1 and 15 of each subsequent cycle ( 2 ).",
    "warningsAndPrecautions_original": "POTELIGEO (mogamulizumab-kpkc) injection is a sterile, preservative-free, clear to slightly opalescent colorless solution supplied in a carton containing one 20 mg/5 mL (4 mg/mL), single-dose glass vial (NDC 42747-761-01).",
    "adverseReactions_original": "None.",
    "drug": [
        {
            "name": "POTELIGEO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB12498"
        }
    ]
}